Response rates of FDA-approved agents for relapsed and refractory aggressive PTCLs
| Agent . | ORR PTCL-NOS (%) . | ORR AITL (%) . | ORR ALCL (%) . |
|---|---|---|---|
| Romidepsin25 | 29 | 30 | 24 |
| Belinostat26 | 23 | 54 | 15 |
| Pralatrexate27 | 32 | 8 | 29 |
| BV12,28 | 33 | 54 | 86 |
| Crizotinib15 | — | — | 88 (ALK+ only) |
| PD-1 inhibition* | — | — | — |
| Agent . | ORR PTCL-NOS (%) . | ORR AITL (%) . | ORR ALCL (%) . |
|---|---|---|---|
| Romidepsin25 | 29 | 30 | 24 |
| Belinostat26 | 23 | 54 | 15 |
| Pralatrexate27 | 32 | 8 | 29 |
| BV12,28 | 33 | 54 | 86 |
| Crizotinib15 | — | — | 88 (ALK+ only) |
| PD-1 inhibition* | — | — | — |
ORR, overall response rate.
Although PD-1 inhibitors, such as nivolumab and pembrolizumab, have been useful in the treatment of relapsed and refractory extranodal T-NK–cell lymphoma, nasal type,29-31 their use in ATLL and other PTCLs has been reported to be associated with hyperprogression.32-34